SAN CARLOS, Calif., Dec. 31 (HSMN NewsFeed) — Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 mi…
Biopharmaceuticals, Drug Delivery, Acquisitions
Nektar Therapeutics, Novartis, Tobramycin

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million”
Leave a Comment